Nutcracker Therapeutics Overview

  • Founded
  • 2017
Founded
  • Status
  • Private
  • Employees
  • 83
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $144M
Latest Deal Amount
  • Investors
  • 4

Nutcracker Therapeutics General Information

Description

Developer of biotech platform disrupter designed for developing mRNA-based therapeutic drug products. The company's platform uses proprietary hardware and software combined with innovations in mRNA biochemistry and nanoparticle delivery to produce optimized mRNA therapies on biochips, enabling clients to discover, develop, and manufacture complex mRNA therapies and vaccines.

Contact Information

Website
www.nutcrackerx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Drug Discovery
Biotechnology
Primary Office
  • 5858 Horton Street
  • Suite 540
  • Emeryville, CA 94608
  • United States
+1 (510) 000-0000

Nutcracker Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nutcracker Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 03-Sep-2021 $144M 00000 00000 Completed Generating Revenue
3. Early Stage VC (Series B) 23-Sep-2020 0000 0000 00000 Completed Startup
2. Angel (individual) 20-Mar-2019 $10M $14M 00000 Completed Startup
1. Angel (individual) 17-May-2018 $4M $4M 00.00 Completed Startup
To view Nutcracker Therapeutics’s complete valuation and funding history, request access »

Nutcracker Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 00,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 7,039,610 $0.000100 6% $1.75 $1.75 1x $1.75 7.93%
Seed 22,857,143 $0.000100 6% $0.17 $0.17 1x $0.17 25.75%
To view Nutcracker Therapeutics’s complete cap table history, request access »

Nutcracker Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of biotech platform disrupter designed for developing mRNA-based therapeutic drug products. The company's plat
Other Healthcare Technology Systems
Emeryville, CA
83 As of 2021
00000
0000 0000-00-00
00000000000 00000

00000000

si ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit ess
0000000000000
Mainz, Germany
0000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nutcracker Therapeutics Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
00000000 Formerly VC-backed Mainz, Germany 0000 00.000 00000000 00.000
You’re viewing 1 of 1 competitors. Get the full list »

Nutcracker Therapeutics Patents

  • 12

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Nutcracker Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210322938-A1 Mixing and microfluidic apparatuses related thereto Pending 23-Dec-2019 000000000000
US-20210322975-A1 Microfluidic apparatuses and methods of use thereof in mixing Pending 23-Dec-2019 000000000000
US-20210039106-A1 Microfluidic apparatus and methods of use thereof Pending 09-Aug-2019 00000000000
US-20210040472-A1 Methods and apparatuses for manufacturing for removing material from a therapeutic composition Pending 09-Aug-2019 00000000000
AU-2019347774-A1 Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery Pending 28-Sep-2018 A61K9/127
To view Nutcracker Therapeutics’s complete patent history, request access »

Nutcracker Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Igor Khandros Ph.D Co-Founder, Chief Executive Officer & Chairman
James Zhu Chief Financial Officer
Benjamin Eldridge Co-Founder & Chief Technology Officer
Madhavan Balachandran Chief Operating Officer
You’re viewing 4 of 5 executive team members. Get the full list »

Nutcracker Therapeutics Board Members (2)

Name Representing Role Since
Igor Khandros Ph.D Nutcracker Therapeutics Co-Founder, Chief Executive Officer & Chairman 000 0000
Robert Nelsen Self Board Member 000 0000
To view Nutcracker Therapeutics’s complete board members history, request access »

Nutcracker Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nutcracker Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Qatar Investment Authority Sovereign Wealth Fund Minority 000 0000 000000 0
Altitude Life Science Ventures Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Bluebird Ventures Venture Capital Minority 000 0000 000000 0
To view Nutcracker Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial